Valerie Kramlinger
Research Subjects
Valerie Kramlinger has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Siamak Cyrus Khojasteh
Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc , South San Francisco, CA 94080
3 shared publications - Upendra A. Argikar
Non-clinical Development, Gates Medical Research Institute
3 shared publications - Aaron M. Teitelbaum
Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, USA
2 shared publications - Amit S. Kalgutkar
Medicine Design, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA
2 shared publications - Bin Ma
Department of Drug Metabolism and Pharmacokinetics Genentech, Inc. South San Francisco CA USA
2 shared publications - Carley J. S. Heck
Medicine Design, Pfizer Worldwide Research, Development and Medical, Groton, CT, USA
2 shared publications
Latest Publications
- 13 August 2025
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 57 (4) , 432-466
Biotransformation research advances – 2024 year in review
This is the ninth installment of this annual review. In line with previous years, the primary objective is to highlight articles deemed by us of significant interest in the broad field of biotransformation. Sixteen manuscripts have been collated and presented herein accompanied by a synopsis, commentary and relevant figures. This year's collection delves into five main areas: 1) the metabolism and disposition of various investigative and approved drugs, 2) non-CYP enzymatic biotransformation, 3) novel models and approaches; 4) the role of gut microbiota, and 5) modulating drug-metabolizing enzyme activities.
- 13 August 2025
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 57 (4) , 432-466
Biotransformation research advances – 2024 year in review
This is the ninth installment of this annual review. In line with previous years, the primary objective is to highlight articles deemed by us of significant interest in the broad field of biotransformation. Sixteen manuscripts have been collated and presented herein accompanied by a synopsis, commentary and relevant figures. This year's collection delves into five main areas: 1) the metabolism and disposition of various investigative and approved drugs, 2) non-CYP enzymatic biotransformation, 3) novel models and approaches; 4) the role of gut microbiota, and 5) modulating drug-metabolizing enzyme activities.
- 28 July 2025
- Published by Taylor & Francis in Drug Metabolism Reviews
- p. 1-38
Bioactivation and reactivity research advances—2024 year in review
Bioactivation continues to be an important aspect of compound evaluation during drug discovery and development, as understanding the metabolic pathways that can lead to the formation of reactive metabolites can facilitate the design of safer drugs. This year's review on bioactivation and reactivity features 17 articles that reflect the latest advances and findings in this research area. This collection of articles is organized into 3 general themes: (1) mechanisms of bioactivation and the impact of bioactivation on safety, (2) new assays for assessing reactive metabolite formation, and (3) computational approaches for predicting reactive metabolite formation.
- 28 July 2025
- Published by Taylor & Francis in Drug Metabolism Reviews
- p. 1-38
Bioactivation and reactivity research advances—2024 year in review
Bioactivation continues to be an important aspect of compound evaluation during drug discovery and development, as understanding the metabolic pathways that can lead to the formation of reactive metabolites can facilitate the design of safer drugs. This year's review on bioactivation and reactivity features 17 articles that reflect the latest advances and findings in this research area. This collection of articles is organized into 3 general themes: (1) mechanisms of bioactivation and the impact of bioactivation on safety, (2) new assays for assessing reactive metabolite formation, and (3) computational approaches for predicting reactive metabolite formation.
- 1 March 2022
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 50 (3) , 258-267
Future of Biotransformation Science in the Pharmaceutical Industry
Over the past decades, the number of scientists trained in departments dedicated to traditional medicinal chemistry, biotransformation and/or chemical toxicology have seemingly declined. Yet, there remains a strong demand for such specialized skills in the pharmaceutical industry, particularly within drug metabolism/pharmacokinetics (DMPK) departments. In this position paper, the members of the Biotransformation, Mechanisms, and Pathways Focus Group (BMPFG) steering committee reflect on the diverse roles and responsibilities of scientists trained in the biotransformation field in pharmaceutical companies and contract research organizations. The BMPFG is affiliated with the International Society for the Study of Xenobiotics (ISSX) and was specifically created to promote the exchange of ideas pertaining to topics of current and future interest involving the metabolism of xenobiotics (including drugs). The authors also delve into the relevant education and diverse training skills required to successfully nurture the future cohort of industry biotransformation scientists and guide them towards a rewarding career path. The ability of scientists with a background in biotransformation/organic chemistry to creatively solve complex drug metabolism problems encountered during research and development efforts on both small molecule or large molecular modalities is exemplified in five relevant case studies. Finally, the authors stress the importance and continued commitment to training the next generation of biotransformation scientists who are not only experienced in the metabolism of conventional small molecule therapeutics, but are also equipped to tackle emerging challenges associated with new drug discovery modalities including peptides, protein degraders and antibodies. Significance Statement Biotransformation and mechanistic drug metabolism scientists are critical to advancing chemical entities through discovery and development, yet the number of scientists academically trained for this role is on the decline. This position paper highlights the continuing demand for biotransformation scientists and the necessity to nurture creative ways to train them and guarantee the future growth of this field.
- 1 March 2022
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 50 (3) , 258-267
Future of Biotransformation Science in the Pharmaceutical Industry
Over the past decades, the number of scientists trained in departments dedicated to traditional medicinal chemistry, biotransformation and/or chemical toxicology have seemingly declined. Yet, there remains a strong demand for such specialized skills in the pharmaceutical industry, particularly within drug metabolism/pharmacokinetics (DMPK) departments. In this position paper, the members of the Biotransformation, Mechanisms, and Pathways Focus Group (BMPFG) steering committee reflect on the diverse roles and responsibilities of scientists trained in the biotransformation field in pharmaceutical companies and contract research organizations. The BMPFG is affiliated with the International Society for the Study of Xenobiotics (ISSX) and was specifically created to promote the exchange of ideas pertaining to topics of current and future interest involving the metabolism of xenobiotics (including drugs). The authors also delve into the relevant education and diverse training skills required to successfully nurture the future cohort of industry biotransformation scientists and guide them towards a rewarding career path. The ability of scientists with a background in biotransformation/organic chemistry to creatively solve complex drug metabolism problems encountered during research and development efforts on both small molecule or large molecular modalities is exemplified in five relevant case studies. Finally, the authors stress the importance and continued commitment to training the next generation of biotransformation scientists who are not only experienced in the metabolism of conventional small molecule therapeutics, but are also equipped to tackle emerging challenges associated with new drug discovery modalities including peptides, protein degraders and antibodies. Significance Statement Biotransformation and mechanistic drug metabolism scientists are critical to advancing chemical entities through discovery and development, yet the number of scientists academically trained for this role is on the decline. This position paper highlights the continuing demand for biotransformation scientists and the necessity to nurture creative ways to train them and guarantee the future growth of this field.
- Open Access
- 24 June 2021
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 53 (3) , 384-433
Novel advances in biotransformation and bioactivation research – 2020 year in review
This annual review is the sixth of its kind since 2016 (see references). Our objective is to explore and share articles which we deem influential and significant in the field of biotransformation and bioactivation. These fields are constantly evolving with new molecular structures and discoveries of corresponding pathways for metabolism that impact relevant drug development with respect to efficacy and safety. Based on the selected articles, we created three sections: (1) drug design, (2) metabolites and drug metabolizing enzymes, and (3) bioactivation and safety (Table 1). Unlike in years past, more biotransformation experts have joined and contributed to this effort while striving to maintain a balance of authors from academic and industry settings.
- 24 June 2021
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 53 (3) , 384-433
Open AccessNovel advances in biotransformation and bioactivation research – 2020 year in review
This annual review is the sixth of its kind since 2016 (see references). Our objective is to explore and share articles which we deem influential and significant in the field of biotransformation and bioactivation. These fields are constantly evolving with new molecular structures and discoveries of corresponding pathways for metabolism that impact relevant drug development with respect to efficacy and safety. Based on the selected articles, we created three sections: (1) drug design, (2) metabolites and drug metabolizing enzymes, and (3) bioactivation and safety (Table 1). Unlike in years past, more biotransformation experts have joined and contributed to this effort while striving to maintain a balance of authors from academic and industry settings.